Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19. (15th May 2020)

• Record Type: Journal Article
• Authors: Hou, H; Zhang, B; Huang, H; Luo, Y; Wu, S; Tang, G; Liu, W; Mao, L; Mao, L; Wang, F; Sun, Z
• Is Part Of: Clinical and experimental immunology. Volume 201:Number 1(2020)
• Page Start: 76
• Page End: 84
• Publication Date: 2020-05-15
• Subjects: clinical progression -- COVID-19 -- cytokine -- IL-2R/lymphocyte ratio -- SARS-CoV-2; Immunopathology -- Periodicals; 616.079
• DOI: 10.1111/cei.13450
• Languages: English
• ISSNs: 0009-9104

Abstract

Summary: Effective laboratory markers for the estimation of disease severity and predicting the clinical progression of coronavirus disease-2019 (COVID-19) is urgently needed. Laboratory tests, including blood routine, cytokine profiles and infection markers, were collected from 389 confirmed COVID-19 patients. The included patients were classified into mild ( n = 168), severe ( n = 169) and critical groups ( n = 52). The leukocytes, neutrophils, infection biomarkers [such as C-reactive protein (CRP), procalcitonin (PCT) and ferritin] and the concentrations of cytokines [interleukin (IL)-2R, IL-6, IL-8, IL-10 and tumor necrosis factor (TNF)-α] were significantly increased, while lymphocytes were significantly decreased with increased severity of illness. The amount of IL-2R was positively correlated with the other cytokines and negatively correlated with lymphocyte number. The ratio of IL-2R to lymphocytes was found to be remarkably increased in severe and critical patients. IL-2R/lymphocytes were superior compared with other markers for the identification of COVID-19 with critical illness, not only from mild but also from severe illness. Moreover, the cytokine profiles and IL-2R/lymphocytes were significantly decreased in recovered patients, but further increased in disease-deteriorated patients, which might be correlated with the outcome of COVID-19. Lymphopenia and increased levels of cytokines were closely associated with disease severity. The IL-2R/lymphocyte was a prominent biomarker for early identification of severe COVID-19 and predicting the clinical progression of the disease. Graphical Abstract: